Female patients who are both lactating and breastfeeding, who have a positive serum pregnancy test during screening, or who plan to become pregnant while in the trial or within  days after receiving protocol-directed treatment
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are nursing or have a positive pregnancy test during screening are not eligible
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are breast feeding or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period.
Female patients who are both lactating and breastfeeding or have positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug (if applicable)
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female subjects who are pregnant or lactating, including females with a positive pregnancy test at screening.
Positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day  before first dose of study drug. Women who are lactating and breastfeeding are not eligible.
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Females who are both lactating and breastfeeding or who have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before first dose of study drug.
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating, breastfeeding, or have a positive pregnancy test
Female patients who are lactating or have a positive pregnancy test during the screening period
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day  before first dose of study drug, if applicable
Female participants who are lactating and breast feeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before first dose of study drug.
Female patients who are lactating or have a positive blood pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day  before first dose of study drug, if applicable
Females patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period.
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
Female patients who are pregnant or breastfeeding or have a positive serum pregnancy test during the screening period
Female patients who are both lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on day  before first dose of study drug
Female patients who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before first dose of study drug
Female subject who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day  before first dose of study drug, if applicable
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day  of any cycle
Female patients who are lactating or have a positive serum or urine pregnancy test during the Screening period.
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before administration of the first dose of study drug.
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.
Female participants who are lactating and breastfeeding or have a positive pregnancy test during the Screening period.
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female patient who are lactating or have a positive serum pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before first dose of alisertib.
Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before first dose of study drug.
Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day  before first dose of study drug, if applicable
Female patients who are lactating or have a positive serum pregnancy test during the screening period, or a positive urine pregnancy test on day  before first dose of study drug, if applicable
Female participants who are both lactating and breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day  before the first dose of study drug
Female participants who are lactating and breast-feeding or a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before the first dose of study drug.
Female patients who are lactating or have a positive pregnancy test during the screening period
Female patients who are lactating or have a positive serum pregnancy test during the screening period
Is female participant who are lactating and breast-feeding or a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day  before the first dose of study drug.
